Pharmacokinetic and pharmacodynamic considerations in gene therapy

被引:99
|
作者
Kamiya, H [1 ]
Akita, H [1 ]
Harashima, H [1 ]
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Mol Design Pharmaceut, Kita Ku, Sapporo, Hokkaido 0600812, Japan
关键词
D O I
10.1016/S1359-6446(03)02889-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During gene therapy the concentration of plasmid DNA or oligonucleotides in the plasma can be quite different from their concentrations in the nucleus or cytosol where they exert their actions. For a better understanding of the apparent discrepancies between pharmacokinetics (PK) and pharmacodynamics (PD), a new concept for intracellular PK with an emphasis on the final efficacy of gene transcription is needed. Here, the conventional PK and intracellular PK and PD of non-viral gene delivery systems are discussed, together with a new concept, referred to as controlled intracellular disposition, which integrates these factors to gain a better understanding of gene expression in the nucleus. The importance of optimizing the system from a transcriptional point of view in the nucleus is also discussed. These new concepts must be integrated to develop an optimized non-viral gene delivery system.
引用
下载
收藏
页码:990 / 996
页数:7
相关论文
共 50 条
  • [1] Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis
    Fujii, Motoki
    Karumai, Toshiyuki
    Yamamoto, Ryohei
    Kobayashi, Eri
    Ogawa, Kenta
    Tounai, Mayuko
    Lipman, Jeffrey
    Hayashi, Yoshiro
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (05) : 415 - 430
  • [2] Sequential antimicrobial therapy: Pharmacokinetic and pharmacodynamic considerations in sequential therapy
    MacGowan, AP
    Bowker, KE
    JOURNAL OF INFECTION, 1998, 37 : 30 - 36
  • [3] Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations
    de Kanter, Clara T. M. M.
    Drenth, Joost P. H.
    Arends, Joop E.
    Reesink, Henk W.
    van der Valk, Marc
    de Knegt, Robert J.
    Burger, David M.
    CLINICAL PHARMACOKINETICS, 2014, 53 (05) : 409 - 427
  • [4] Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations
    Clara T. M. M. de Kanter
    Joost P. H. Drenth
    Joop E. Arends
    Henk W. Reesink
    Marc van der Valk
    Robert J. de Knegt
    David M. Burger
    Clinical Pharmacokinetics, 2014, 53 : 409 - 427
  • [5] CIGARETTES AND DRUG-THERAPY - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
    MILLER, LG
    CLINICAL PHARMACY, 1990, 9 (02): : 125 - 135
  • [6] Gene Therapy: A Pharmacokinetic/Pharmacodynamic Modelling Overview
    Zinnia P. Parra-Guillén
    Gloria González-Aseguinolaza
    Pedro Berraondo
    Iñaki F. Trocóniz
    Pharmaceutical Research, 2010, 27 : 1487 - 1497
  • [7] Gene Therapy: A Pharmacokinetic/Pharmacodynamic Modelling Overview
    Parra-Guillen, Zinnia P.
    Gonzalez-Aseguinolaza, Gloria
    Berraondo, Pedro
    Troconiz, Inaki F.
    PHARMACEUTICAL RESEARCH, 2010, 27 (08) : 1487 - 1497
  • [8] PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS IN DRUG-THERAPY OF CARDIAC EMERGENCIES
    PENTEL, P
    BENOWITZ, N
    CLINICAL PHARMACOKINETICS, 1984, 9 (04) : 273 - 308
  • [9] Pharmacokinetic considerations in somatic gene therapy
    Ledley, FD
    Ledley, TS
    ADVANCED DRUG DELIVERY REVIEWS, 1998, 30 (1-3) : 133 - 150
  • [10] Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
    Smolders, Elise J.
    Jansen, Anouk M. E.
    ter Horst, Peter G. J.
    Rockstroh, Juergen
    Back, David J.
    Burger, David M.
    CLINICAL PHARMACOKINETICS, 2019, 58 (10) : 1237 - 1263